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Summary
Background It is unclear whether radial compared with femoral access improves outcomes in unselected patients 
with acute coronary syndromes undergoing invasive management.
Methods We did a randomised, multicentre, superiority trial comparing transradial against transfemoral access in 
patients with acute coronary syndrome with or without ST-segment elevation myocardial infarction who were 
about to undergo coronary angiography and percutaneous coronary intervention. Patients were randomly allocated 
(1:1) to radial or femoral access with a web-based system. The randomisation sequence was computer generated, 
blocked, and stratiﬁ ed by use of ticagrelor or prasugrel, type of acute coronary syndrome (ST-segment elevation 
myocardial infarction, troponin positive or negative, non-ST-segment elevation acute coronary syndrome), and 
anticipated use of immediate percutaneous coronary intervention. Outcome assessors were masked to treatment 
allocation. The 30-day coprimary outcomes were major adverse cardiovascular events, deﬁ ned as death, myocardial 
infarction, or stroke, and net adverse clinical events, deﬁ ned as major adverse cardiovascular events or Bleeding 
Academic Research Consortium (BARC) major bleeding unrelated to coronary artery bypass graft surgery. 
The analysis was by intention to treat. The two-sided α was prespeciﬁ ed at 0·025. The trial is registered at 
ClinicalTrials.gov, number NCT01433627.
Findings We randomly assigned 8404 patients with acute coronary syndrome, with or without ST-segment elevation, 
to radial (4197) or femoral (4207) access for coronary angiography and percutaneous coronary intervention. 
369 (8·8%) patients with radial access had major adverse cardiovascular events, compared with 429 (10·3%) patients 
with femoral access (rate ratio [RR] 0·85, 95% CI 0·74–0·99; p=0·0307), non-signiﬁ cant at α of 0·025. 410 (9·8%) 
patients with radial access had net adverse clinical events compared with 486 (11·7%) patients with femoral access 
(0·83, 95% CI 0·73–0·96; p=0·0092). The diﬀ erence was driven by BARC major bleeding unrelated to coronary 
artery bypass graft surgery (1·6% vs 2·3%, RR 0·67, 95% CI 0·49–0·92; p=0·013) and all-cause mortality (1·6% vs 
2·2%, RR 0·72, 95% CI 0·53–0·99; p=0·045).
Interpretation In patients with acute coronary syndrome undergoing invasive management, radial as compared 
with femoral access reduces net adverse clinical events, through a reduction in major bleeding and all-cause 
mortality.
Funding The Medicines Company and Terumo.
Introduction
Over the past two decades early invasive management and 
the use of combined antithrombotic therapies have 
lowered the risk of recurrent myocardial infarction in 
patients with acute coronary syndromes, but have also 
been associated with a signiﬁ cant increase in bleeding.1,2 
Bleeding is associated with worse short-term and 
long-term clinical outcomes, and this relation is thought 
to be causal.3,4 Therefore, reducing the frequency of 
bleeding events while maintaining eﬀ ective ness is an 
important goal in the management of patients with acute 
coronary syndrome, and has the potential to reduce 
mortality, morbidity, and costs.5
A common site of bleeding in invasively managed 
patients is at the femoral artery puncture site used for 
heart catheterisation.6 Compared with the femoral 
artery, the radial artery is more superﬁ cial and has a 
smaller calibre. Radial access is therefore technically 
more demanding, but makes access site haemostasis 
more predictable.7 Previous studies have come to 
diﬀ ering conclusions about the role of radial access 
in reducing adverse outcomes in patients with acute 
coronary syndrome undergoing catheterisation or 
percutaneous coronary intervention.8,9 Whether avoiding 
access site bleeding and vascular complications by 
the use of routine transradial intervention improves 
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outcomes in largely unselected patients with acute 
coronary syndrome undergoing invasive management 
remains unclear.8
Therefore, we did a large, multicentre, randomised 
trial in patients with acute coronary syndrome who were 
about to undergo coronary angiography and possible per-
cutaneous coronary intervention, if indicated, to assess 
whether radial access is superior to femoral access.
Methods
Study design and participants
Minimizing Adverse Haemorrhagic Events by 
TRansradial Access Site and Systemic Implementation 
of angioX (MATRIX Access) was a randomised 
multicentre super iority trial comparing transradial 
against trans femoral access in patients with acute 
coronary syndrome with or without ST-segment 
elevation myo cardial in farction who were about to 
undergo coronary angio graphy and per cutaneous 
coronary inter vention, if indicated.10,11 This trial is part of 
the MATRIX pro gramme (registered at ClinicalTrials.
gov, number NCT01433627), and was done in all 
patients with an acute coronary syndrome con senting to 
participate in the programme. The pro gramme was 
done in 78 centres in Italy, the Netherlands, Spain, and 
Sweden. Results of subsequent, nested trials will be 
reported separately. 
Patients were eligible if they had an acute coronary 
syndrome with or without ST-segment elevation myo-
cardial infarction, were about to undergo an invasive 
approach, and the interventional cardiologist was 
willing to proceed with either radial or femoral access 
and had expertise for both, including at least 75 coronary 
inter ventions performed, and at least 50% of inter-
ventions in acute coronary syndrome via the radial 
route during the previous year (appendix). Patients 
presenting with non-ST-segment elevation acute 
coronary syndrome were eligible if they had a history 
consistent with new or worsening ischaemia, occurring 
at rest or with minimal activity within 7 days before 
randomisation, and fulﬁ lled at least two high-risk 
criteria (detailed in the appendix). Patients with 
ST-segment elevation myocardial infarction were 
eligible if they presented within 12 h of the onset of 
symptoms or between 12 and 24 h after onset if there 
was evidence of continuing ischaemia or previous 
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Figure 1: Trial proﬁ le
*Technical failure of the x-ray system (one patient); angiography aborted due to cerebrovascular event (one patient). †Refused angiography (ﬁ ve patients); 
angiography aborted due to a cerebrovascular event (one patient).
8404 patients randomly assigned
4197 allocated to radial access 
3 radial access not attempted 
 1 received femoral access  
 2 no complete angiography performed* 
13 femoral access not attempted 
 7 received radial access 
 6 no complete angiography performed†
4207 allocated to femoral access 
4194 attempted radial access
 3951 received radial access
 243 failed radial access
 241 received femoral access
 2 received brachial access
4194 attempted femoral access
 4098 received femoral access
 96 failed femoral access
 95 received radial access
 1 received brachial access
14 follow-up information incomplete
 13 lost to follow-up before 30 days
 1 refused follow-up 
16 follow-up information incomplete 
 10 lost to follow-up before 30 days 
 6 refused follow-up 
4183 follow-up information for 
 coprimary endpoints available up 
 to 30 days 
 4117 followed up and alive 
 66 followed up and died 
4191 follow-up information for 
 coprimary endpoints available up 
 to 30 days 
 4100 followed up and alive 
 91 followed up and died 
4197 analysed for coprimary endpoints 4207 analysed for coprimary endpoints
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ﬁ brinolytic treatment, and if they had ST-segment 
elevation of at least 1 mm in two or more contiguous 
leads, new left bundle-branch block, or true posterior 
myocardial infarction. Patients with cardiogenic shock, 
severe peripheral vascular disease, or previous coronary 
artery bypass graft surgery were deemed eligible. The 
principal exclusion criteria were use of low-molecular-
weight heparin in the previous 6 h, glycoprotein 
IIb/IIIa inhibitors in the previous 3 days, or any 
percutaneous coronary intervention done in the 
previous 30 days (appendix). The trial was approved by 
the institutional review board at each participating 
centre, and all patients gave written informed consent 
to participate.
Randomisation and masking
Before start of angiography, patients were centrally 
allocated (1:1) to radial or femoral access for diagnostic 
angiography and percutaneous coronary intervention, 
if indicated, using a web-based system to ensure 
adequate concealment of allocation. The randomisation 
sequence was computer generated, blocked and 
stratiﬁ ed by intended new or ongoing use of ticagrelor 
or prasugrel, type of acute coronary syndrome 
(ST-segment elevation myo cardial infarction, troponin 
positive or negative, non-ST-segment elevation acute 
coronary syndrome), and anti cipated use of immediate 
percutaneous coronary inter vention. Outcome assess-
ors were masked to the allocated stent, whereas patients 
and treating physicians were not. Information on the 
patency of the ulno-palmar arches, according to the 
modiﬁ ed Allen’s and Barbeau’s tests, was collected after 
randomisation.10,12
Radial access 
(n=4197)
Femoral access 
(n=4207)
Age (years) 65·6 (11·8) 65·9 (11·8)
≥75 years 1068 (25·4%) 1102 (26·2%)
Men 3126 (74·5%) 3046 (72·4%)
Weight (kg) 77·4 (14·3) 77·0 (13·6)
BMI (kg/m²) 27·1 (4·2) 27·1 (4·2)
≥25 kg/m² 2797 (66·6%) 2816 (66·9%)
Diabetes 951 (22·7%) 932 (22·2%)
Insulin-dependent 204 (4·9%) 250 (5·9%)
Non-insulin-dependent 747 (17·8%) 682 (16·2%)
Smoker 2268 (54·0%) 2269 (53·9%)
Current 1459 (34·8%) 1428 (33·9%)
Previous 809 (19·3%) 841 (20·0%)
Hypercholesterolaemia 1799 (42·9%) 1892 (45·0%)
Hypertension 2625 (62·5%) 2686 (63·8%)
Family history of coronary artery 
disease
1146 (27·3%) 1147 (27·3%)
Previous myocardial infarction 585 (13·9%) 617 (14·7%)
Previous PCI 610 (14·5%) 585 (13·9%)
Radial access only 119 (2·8%) 84 (2·0%)
Femoral access only 276 (6·6%) 286 (6·8%)
Radial and femoral access 36 (0·9%) 35 (0·8%)
Access site unknown 179 (4·3%) 180 (4·3%)
Previous coronary artery bypass graft 111 (2·6%) 146 (3·5%)
Previous TIA or stroke 195 (4·6%) 230 (5·5%)
Peripheral vascular disease 341 (8·1%) 372 (8·8%)
Chronic obstructive pulmonary disease 250 (6·0%) 283 (6·7%)
Pulmonary hypertension 8 (0·2%) 7 (0·2%)
Renal failure 46 (1·1%) 59 (1·4%)
Dialysis 4 (0·1%) 4 (0·1%)
Clinical presentation
Cardiac arrest 84 (2·0%) 82 (1·9%)
Killip class
I 3796 (90·4%) 3800 (90·3%)
II 268 (6·4%) 301 (7·2%)
III 88 (2·1%) 79 (1·9%)
IV 45 (1·1%) 27 (0·6%)
STEMI 2001 (47·7%) 2009 (47·8%)
(Table 1 continues in next column)
Radial access 
(n=4197)
Femoral access 
(n=4207)
(Continued from previous column)
NSTE-ACS 2196 (52·3%) 2198 (52·2%)
NSTE-ACS, troponin negative 243 (5·8%) 269 (6·4%)
NSTE-ACS, troponin positive 1953 (46·5%) 1929 (45·9%)
NSTE-ACS with ST-segment 
deviation
1015 (24·2%) 987 (23·5%)
NSTE-ACS with T-wave inversion 657 (15·7%) 676 (16·1%)
Systolic blood pressure (mm Hg) 138·5 (25·5) 138·8 (25·7)
Heart rate (beats per min) 76·3 (16·6) 76·0 (16·8)
Left ventricular ejection fraction (%) 51·3 (9·6) 50·8 (9·8)
Estimated glomerular ﬁ ltration rate 
(mL/min)
83·9 (25·5) 83·1 (25·5)
Medications given before the 
catheterisation laboratory
Aspirin 3953 (94·2%) 3952 (93·9%)
Clopidogrel 2014 (48·0%) 1996 (47·4%)
Prasugrel 484 (11·5%) 468 (11·1%)
Ticagrelor 977 (23·3%) 1026 (24·4%)
Enoxaparin 684 (16·3%) 738 (17·5%)
Fondaparinux 428 (10·2%) 467 (11·1%)
Angiotensin-converting enzyme 
inhibitor
1245 (29·7%) 1297 (30·8%)
Angiotensin II receptor antagonist 437 (10·4%) 458 (10·9%)
Statin 1809 (43·1%) 1858 (44·2%)
β blocker 1692 (40·3%) 1769 (42·0%)
Warfarin 72 (1·7%) 64 (1·5%)
Proton pump inhibitor 2153 (51·3%) 2190 (52·1%)
Unfractionated heparin 1239 (29·5%) 1236 (29·4%)
Bivalirudin 4 (0·1%) 2 (0·0%)
Glycoprotein IIb/IIIa inhibitor 8 (0·2%) 7 (0·2%)
Data are n (%) or mean (SD). NSTE-ACS=non-ST-segment elevation acute coronary 
syndrome. STEMI=ST-segment elevation myocardial infarction. TIA=transient 
ischaemic attack.
Table 1: Baseline characteristics of the intention-to-treat population 
according to access site 
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Procedures
Access site management during and after the diagnostic 
or therapeutic procedure was at the discretion of the 
treating physician, and closure devices were allowed as 
per local practice. The use of anticoagulants outside the 
protocol of the MATRIX programme was not allowed. 
Bivalirudin administration was consistent with the 
approved product labelling, whereas unfractionated 
heparin was dosed at 70–100 units per kg in patients not 
receiving glycoprotein IIb/IIIa inhibitors and at 
50–70 units per kg in patients receiving glycoprotein 
IIb/IIIa inhibitors. Use of all other antithrombotic 
medi cations, including oral antiplatelet agents and 
non-anti thrombotic medications, such as β blockers, 
angio tensin-converting enzyme inhibitors, and other 
anti hyper tensive agents, were allowed as per guide-
lines.1,2 Staged procedures were allowed, with no 
restriction with respect to timing, during which the 
protocol mandated that the access site remained as 
originally allocated. Clinical follow-up was done at 
30 days, with an extended follow-up at 1 year.
Outcomes
Two coprimary 30-day composite outcomes were 
prespeciﬁ ed: major adverse cardiovascular events, 
deﬁ ned as the composite of all-cause mortality, 
myocardial infarction, or stroke; and net adverse 
clinical events, deﬁ ned as the composite of major 
bleeding not related to coronary artery bypass graft 
surgery (Bleeding Academic Research Consortium 
[BARC] type 3 or 5) or major adverse cardiovascular 
events.10 Secondary outcomes included each component 
of the composite outcomes, cardiovascular mortality, 
and stent thrombosis. Bleeding was also assessed and 
adjudicated on the basis of the Thrombolysis In 
Myocardial Infarction (TIMI) and Global Utilization of 
Streptokinase and Tissue Plasminogen Activator for 
Occluded Coronary Arteries (GUSTO) scales. Stent 
thrombosis was deﬁ ned as the deﬁ nite or probable 
occurrence of a stent-related thrombotic event 
according to the Academic Research Consortium 
classiﬁ cation.13 All outcomes were prespeciﬁ ed.10 An 
independent clinical events committee masked to 
treatment allocation adjudicated all suspected outcome 
events by reviewing relevant medical records after site 
monitoring by Trial Form Support (Lund, Sweden) 
in Italy and the Netherlands, FLS-Research Support 
(Barcelona, Spain) in Spain, and Gothia Forum (Västra 
Götaland, Sweden) in Sweden. Procedural success in a 
treated lesion was deﬁ ned as reaching a post-procedure 
TIMI 3 ﬂ ow and less than 30% coronary stenosis.
Statistical analysis
The trial was powered for superiority on the 
two coprimary composite outcomes at 30 days. For 
major adverse cardiovascular events, we expected rates 
of 6·0% in the femoral group and 4·2% in the radial 
Radial access 
(n=4197)
Femoral access 
(n=4207)
p value
Coronary angiography
Attempted coronary angiography 4197 (100%) 4207 (100%)
Coronary angiography not completed 2 (0·0%) 6 (0·1%) 0·29
Patient refusal 0 (0·0%) 5 (0·1%) 0·062
Technical issue 1 (0·0%) 0 (0·0%) 0·50
Non-fatal cardiovascular accident 1 (0·0%) 1 (0·0%) 1·00
Coronary angiography completed 4195 (100·0%) 4201 (99·9%) 0·29
No PCI attempted after coronary angiography 826 (19·7%) 843 (20·0%) 0·68
CABG 155 (3·7%) 155 (3·7%) 0·98
Patient with signiﬁ cant lesion and medical 
treatment
490 (11·7%) 499 (11·9%) 0·79
Patient without signiﬁ cant lesion 181 (4·3%) 189 (4·5%) 0·69
PCI attempted 3369 (80·3%) 3358 (79·8%) 0·60
Patient died during PCI 1 (0·0%) 1 (0·0%) 1·00
PCI completed 3368 (80·2%) 3357 (79·8%) 0·60
Medications in the catheterisation laboratory
Clopidogrel 270 (6·4%) 254 (6·0%) 0·45
Prasugrel 336 (8·0%) 290 (6·9%) 0·0521
Ticagrelor 382 (9·1%) 397 (9·4%) 0·60
Glycoprotein IIb/IIIa inhibitor 574 (13·7%) 520 (12·4%) 0·07
Unfractionated heparin 2094 (49·9%) 1916 (45·5%) 0·0001
Bivalirudin 1683 (40·1%) 1712 (40·7%) 0·58
Intra-aortic balloon pump 79 (1·9%) 95 (2·3%) 0·23
PCIs
Number of PCIs completed 3368 3357
TIMI 3 ﬂ ow post-procedure in all treated lesions 3195 (94·9%) 3195 (95·2%) 0·56
Coronary stenosis after PCI <30% in all treated 
lesions
3221 (95·6%) 3201 (95·4%) 0·58
Procedural success in all treated lesions 3122 (92·7%) 3115 (92·8%) 0·88
Partial procedural success* 61 (1·8%) 66 (2·0%) 0·64
Procedural failure 185 (5·5%) 176 (5·2%) 0·65
Treated vessel(s)
Left main coronary artery 154 (4·6%) 119 (3·5%) 0·0328
Left anterior descending artery 1694 (50·3%) 1653 (49·2%) 0·39
Left circumﬂ ex artery 906 (26·9%) 922 (27·5%) 0·60
Right coronary artery 1120 (33·3%) 1130 (33·7%) 0·72
Bypass graft 20 (0·6%) 37 (1·1%) 0·0230
≥2 vessels treated 463 (13·7%) 460 (13·7%) 0·96
Lesions treated per patient 1·0 (1·0–1·0) 1·0 (1·0–1·0) 0·75
1 2642 (78·4%) 2657 (79·1%)
2 594 (17·6%) 577 (17·2%)
≥3 132 (3·9%) 123 (3·7%)
≥1 complex lesion 1780 (52·9%) 1720 (51·2%) 0·19
Number of stents per patient 1·0 (1·0–2·0) 1·0 (1·0–2·0) 0·19†
Overall stent length per patient (mm) 31·8 (19·2) 31·4 (19·4) 0·42
Thromboaspiration 964 (28·6%) 1004 (29·9%) 0·25
Lesions‡
Number of lesions with PCI 4258 4201
Lesions stented 3881 (91·1%) 3797 (90·4%) 0·22
≥1 drug-eluting stent 2822 (66·3%) 2800 (66·7%) 0·81
≥1 bare-metal stent 1059 (24·9%) 997 (23·7%) 0·30
(Table 2 continues on next page)
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group, corresponding to a rate ratio (RR) of 0·70. For 
net adverse clinical events, we expected rates of 9·0% 
in the femoral group and 6·3% in the radial group, 
again corresponding to an RR of 0·70. A total of 
4100 patients per group would provide greater than 
90% power for these diﬀ erences to be detected for the 
ﬁ rst coprimary outcome and greater than 99% power 
for the second coprimary outcome, with a two-sided α 
set at 2·5%. The ﬁ nal sample size was driven by the 
power analysis for the nested MATRIX anti-thrombin 
trial,10 taking into account the fact that patients with 
non-ST-segment elevation acute coronary syndrome 
were eligible only if proceeding to percutaneous 
coronary intervention. No interim analysis was 
prespeciﬁ ed or done. We analysed secondary outcomes 
with a two-sided α set at 5% to allow conventional 
interpretation of results.
We did all analyses according to the intention-to-treat 
principle, including all patients in the analysis 
according to the allocated access. We analysed primary 
and secondary outcomes as time-to-ﬁ rst-event using 
the Mantel–Cox method, accompanied by log-rank 
tests to calculate corresponding two-sided p values. 
Survival curves were constructed using Kaplan-Meier 
estimates. We stratiﬁ ed analyses according to 
prespeciﬁ ed sub groups including age, sex, BMI, 
presenting syndrome, type of P2Y12 inhibitor, overall or 
transradial percutaneous coronary intervention volume 
by centre, renal function, diabetes, and peripheral 
vascular disease, and with χ² tests for interaction or 
tests for trend across ordered groups.
We did a post-hoc nested case-control study to 
examine factors associated with deaths not directly 
attributed to a bleeding event. Cases were deﬁ ned as all 
patients who died up to 30 days after randomisation 
from a cause other than bleeding (ie, we excluded 
BARC type 5 bleedings). Ten control patients per case 
were randomly selected from the overall cohort of 
randomised patients to construct a matched case-control 
set for each case. To qualify as control, the patient had 
to be alive until the time the case patient had died. We 
ﬁ tted conditional logistic regression models to obtain 
odds ratios (ORs) and 95% CIs for the association 
of characteristics of patients at baseline and BARC 
type 2 or 3 actionable bleedings with deaths from 
causes other than bleeding. We did crude univariable 
analyses for all variables. The ﬁ nal multivariable model 
was based on all variables associated with the 
case-control status, with automated hierarchical 
backward selection of variables. p was 0·10 for initial 
inclusion and retention of variables in the model. All 
analyses were done in Stata Release 13.
Role of the funding source
The programme was designed by the principal 
investigator (MV), sponsored by the Gruppo Italiano 
Studi Emodinamica (GISE), a non-proﬁ t organisation, 
Radial access 
(n=4197)
Femoral access 
(n=4207)
p value
(Continued from previous page)
Lesions not stented 377 (8·9%) 404 (9·6%) 0·22
TIMI ﬂ ow before PCI
0 or 1 1628 (38·2%) 1623 (38·6%) 0·93
2 533 (12·5%) 532 (12·7%) 0·78
3 2097 (49·2%) 2046 (48·7%) 0·98
TIMI ﬂ ow after PCI
0 or 1 76 (1·8%) 71 (1·7%) 0·76
2 107 (2·5%) 102 (2·4%) 0·80
3 4075 (95·7%) 4028 (95·9%) 0·64
Coronary stenosis after PCI <30% 4097 (96·2%) 4036 (96·1%) 0·66
Procedural success 3989 (93·7%) 3944 (93·9%) 0·77
Number of lesions stented 3881 3797
Total stent length per lesion (mm) 25·9 (14·4) 25·9 (14·1) 0·81
Average stent diameter per lesion (mm) 3·1 (0·5) 3·0 (0·5) 0·29
≥1 direct stenting 864 (22·3%) 840 (22·1%) 0·87
Post-stenting dilatation 1726 (44·5%) 1717 (45·2%) 0·57
Data are n (%), mean (SD), or median (IQR). PCI=percutaneous coronary intervention. TIMI=Thrombolysis in 
Myocardial Infarction. *TIMI 3 ﬂ ow and coronary stenosis less than 30% in at least one lesion. †p value for count from 
Poisson regression. ‡p values from mixed models accounting for lesions nested within patients.
Table 2: Procedural characteristics in patients undergoing attempted coronary angiography 
Radial access 
(n=4197)
Femoral access 
(n=4207)
Rate ratio
(95% CI)
p value
Adjudicated events
Coprimary composite of all-cause 
mortality, myocardial infarction, or 
stroke
369 (8·8%) 429 (10·3%) 0·85 (0·74–0·99) 0·0307
Coprimary composite of all-cause 
mortality, myocardial infarction, 
stroke, or BARC 3 or 5 bleed
410 (9·8%) 486 (11·7%) 0·83 (0·73–0·96) 0·0092
Composite of all-cause mortality, 
myocardial infarction, stroke, urgent 
TVR, deﬁ nite stent thrombosis, or 
BARC 3 or 5 bleed
419 (10·0%) 491 (11·8%) 0·84 (0·74–0·97) 0·0142
All-cause mortality 66 (1·6%) 91 (2·2%) 0·72 (0·53–0·99) 0·0450
Cardiovascular 64 (1·5%) 85 (2·1%) 0·75 (0·54–1·04) 0·08
Cardiac 62 (1·5%) 79 (1·9%) 0·78 (0·56–1·09) 0·15
Vascular 2 (0·0%) 6 (0·1%) 0·33 (0·07–1·65) 0·16
Non-cardiovascular 2 (0·0%) 6 (0·2%) 0·33 (0·07–1·65) 0·16
Myocardial infarction 299 (7·2%) 330 (7·9%) 0·90 (0·77–1·06) 0·20
Q-wave 6 (0·1%) 3 (0·1%) 2·00 (0·50–7·99) 0·32
STEMI 37 (0·9%) 30 (0·7%) 1·23 (0·76-2·00) 0·39
NSTEMI 197 (4·7%) 238 (5·7%) 0·82 (0·68–1·00) 0·0450
Unclassiﬁ ed* 65 (1·6%) 63 (1·5%) 1·03 (0·73–1·46) 0·86
Stroke 16 (0·4%) 16 (0·4%) 1·00 (0·50–2·00) 1·00
Ischaemic 12 (0·3%) 11 (0·3%) 1·09 (0·48–2·47) 0·84
Haemorrhagic 3 (0·1%) 5 (0·1%) 0·60 (0·14–2·51) 0·48
Uncertain origin† 1 (0·0%) 0 (0·0%) 3·01 (0·12–73·87) 0·50
Transient ischaemic attack 5 (0·1%) 13 (0·3%) 0·38 (0·14–1·08) 0·0588
Urgent target vessel revascularisation 49 (1·2%) 40 (1·0%) 1·23 (0·81–1·86) 0·34
(Table 3 continues on next page)
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and received grant support from The Medicines 
Company and TERUMO (appendix). Sponsors and 
companies had no role in study design, data collection, 
data monitoring, analysis, interpretation, or writing of 
the report. MV, MR, DH, and PJ had unrestricted 
access to all the data of the trial. MV and PJ had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between Oct 11, 2011, and Nov 7, 2014, 8404 patients were 
randomly allocated to receive radial (4197 patients) or 
femoral access (4207 patients). Of these patients, 
3951 (94·1%) received radial access and 4098 (97·4%) 
received femoral access. Access was attempted but failed 
in 243 (5·8%) radial patients and 96 (2·3%) femoral 
patients, and access was not attempted in three (0·1%) 
radial and 13 (0·3%) femoral patients. Complete follow-up 
to 30 days was available in 4183 radial and 4191 femoral 
patients (ﬁ gure 1). Baseline characteristics were similar 
between groups (table 1). Overall, 4010 (47·7%) patients 
had an ST-segment elevation myocardial infarction and 
4394 (52·3%) patients had non-ST-segment elevation 
acute coronary syndrome. Clopidogrel was given before 
angio graphy in 4010 (47·7%) patients, ticagrelor in 2003 
(23·8%) patients, and prasugrel in 952 (11·3%) patients.
Procedural results according to access strategy are 
presented in table 2. The management strategy after index 
angiography was similar in both groups, consisting of 
percutaneous coronary intervention in 6727 (80·1%) 
patients, coronary artery bypass graft surgery in 310 (3·7%) 
patients, and medical management in 1359 (16·2%) 
patients. In the catheterisation laboratory, 2094 (49·9%) 
patients received unfractionated heparin in the radial 
group and 1916 (45·5%) patients in the femoral group 
(p<0·0001), 574 (13·7%) patients received glycoprotein 
IIb/IIIa inhibitors in the radial group and 520 (12·4%) 
patients in the femoral group (p=0·07), and 1683 (40·1%) 
patients were treated with bivalirudin in the radial group 
and 1712 (40·7%) patients in the femoral group (p=0·58). 
Among patients with percutaneous coronary intervention, 
procedural success was achieved in all treated lesions in 
3122 (92·7%) radial patients and 3115 (92·8%) femoral 
patients. Results of staged procedures and medications at 
discharge are detailed in the appendix.
Clinical outcomes are shown in table 3,  ﬁ gures 2 and 3. 
The ﬁ rst coprimary outcome of major adverse cardiac 
events occurred in 369 (8·8%) patients with radial access 
and 429 (10·3%) patients with femoral access, with a RR 
of 0·85 (95% CI 0·74–0·99) and a two-sided p of 0·0307, 
which was formally non-signiﬁ cant at the prespeciﬁ ed α 
of 0·025. The second coprimary outcome of net adverse 
clinical events was experienced by 410 (9·8%) patients 
with radial access and 486 (11·7%) patients with femoral 
access, with a formally signiﬁ cant RR of 0·83 (95% CI 
0·73–0·96; p=0·0092). Radial access was associated with 
a lower risk of all-cause mortality (table 3, ﬁ gure 3); rates 
of cardiac mortality, myocardial infarction, and stroke 
were not signiﬁ cantly diﬀ erent (table 3, ﬁ gure 3). The 
two groups had similar rates of urgent target vessel 
revascularisation and stent thrombosis. Major BARC 3 or 
5 bleeding was signiﬁ cantly reduced in the radial group 
Radial access 
(n=4197)
Femoral access 
(n=4207)
Rate ratio
(95% CI)
p value
(Continued from previous page)
Stent thrombosis
Deﬁ nite 30 (0·7%) 27 (0·6%) 1·11 (0·66–1·87) 0·69
Acute 21 (0·5%) 12 (0·3%) 1·75 (0·86–3·57) 0·12
Subacute 10 (0·2%) 15 (0·4%) 0·66 (0·30–1·48) 0·31
Deﬁ nite or probable 42 (1·0%) 38 (0·9%) 1·10 (0·71–1·71) 0·66
Acute 24 (0·6%) 14 (0·3%) 1·72 (0·89–3·32) 0·11
Subacute 20 (0·5%) 24 (0·6%) 0·83 (0·46–1·50) 0·54
Bleeding 350 (8·4%) 606 (14·6%) 0·55 (0·48–0·63) <0·0001
BARC classiﬁ cation
Type 1 168 (4·0%) 306 (7·4%) 0·54 (0·44–0·65) <0·0001
Type 2 127 (3·1%) 215 (5·2%) 0·58 (0·47–0·73) <0·0001
Type 3 54 (1·3%) 84 (2·1%) 0·64 (0·45–0·90) 0·0098
Type 3a 29 (0·7%) 44 (1·1%) 0·66 (0·41–1·05) 0·08
Type 3b 23 (0·6%) 37 (0·9%) 0·62 (0·37–1·04) 0·07
Type 3c 2 (0·0%) 4 (0·1%) 0·50 (0·09–2·72) 0·41
Type 4 6 (0·1%) 6 (0·1%) 1·00 (0·32–3·10) 1·00
Type 5 10 (0·2%) 11 (0·3%) 0·91 (0·39–2·14) 0·82
Type 5a 6 (0·1%) 9 (0·2%) 0·67 (0·24–1·87) 0·44
Type 5b 4 (0·1%) 2 (0·0%) 2·00 (0·37–10·92) 0·41
Type 3 or 5 64 (1·6%) 95 (2·3%) 0·67 (0·49–0·92) 0·0128
Related to access site 16 (0·4%) 43 (1·1%) 0·37 (0·21–0·66) 0·0004
Not related to access site 48 (1·2%) 52 (1·3%) 0·92 (0·62–1·36) 0·68
Type 2, 3, or 5 189 (4·6%) 307 (7·4%) 0·60 (0·50–0·73) <0·0001
Related to access site 69 (1·7%) 197 (4·8%) 0·34 (0·26–0·45) <0·0001
Not related to access site 121 (2·9%) 115 (2·8%) 1·05 (0·81–1·36) 0·70
TIMI classiﬁ cation
Major bleeding 26 (0·6%) 37 (0·9%) 0·70 (0·42–1·16) 0·16
Minor bleeding 24 (0·6%) 32 (0·8%) 0·75 (0·44–1·27) 0·28
Major or minor bleeding 50 (1·2%) 69 (1·7%) 0·72 (0·50–1·04) 0·08
GUSTO classiﬁ cation
Severe bleeding 23 (0·6%) 27 (0·6%) 0·85 (0·49–1·48) 0·57
Moderate bleeding 23 (0·6%) 32 (0·8%) 0·72 (0·42–1·22) 0·22
Mild bleeding 306 (7·4%) 549 (13·3%) 0·54 (0·47–0·62) <0·0001
Moderate or severe bleeding 46 (1·1%) 59 (1·4%) 0·78 (0·53–1·14) 0·20
Non-adjudicated events
Composite of surgical access site 
repair or blood products transfusion
41 (1·0%) 73 (1·8%) 0·56 (0·38-0·82) 0·0025
Surgical access site repair 4 (0·1%)‡ 15 (0·4%) 0·27 (0·09–0·80) 0·0115
Red blood cell transfusion 40 (1·0%) 64 (1·5%) 0·62 (0·42-0·92) 0·0176
Percentages are cumulative incidence estimates. BARC=Bleeding Academic Research Consortium. GUSTO=Global 
Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. MI=myocardial 
infarction. NSTEMI=non-ST-segment elevation myocardial infarction. STEMI=ST-segment elevation myocardial 
infarction. TIMI=Thrombolysis In Myocardial Infarction. TVR=target vessel revascularisation. *Includes patients 
with left bundle-branch block and patients with paced rhythm. †Continuity corrected rate ratio (95% CI) with 
p value from Fisher’s test. ‡Occurred in one patient at the radial artery access site due to a large haematoma and 
in three patients at the femoral access site, which was used for inserting an intra-aortic balloon pump or after 
failed radial access. 
 Table 3: Adjudicated and non-adjudicated clinical outcomes
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(table 3, ﬁ gure 3), as were minor non-actionable BARC 1 
and actionable BARC 2 bleeding. Bleeding events 
fulﬁ lling the TIMI or GUSTO criteria did not diﬀ er 
signiﬁ cantly between groups, but the estimated relative 
risk reductions were consistent with what we noted for 
major BARC 3 or 5 bleeding. Radial access was associated 
with signiﬁ cantly lower rates of surgical access site 
repair or transfusion of blood products. No cases of 
compartment syndrome were reported.
Figure 4 and the appendix show the stratiﬁ ed analyses of 
the two coprimary outcomes, all-cause mortality, and 
BARC 3 or 5 bleeding. The eﬀ ect of radial versus femoral 
access appeared consistent across major patient subgroups 
deﬁ ned by acute coronary syndrome type, age, sex, BMI, 
intended start or ongoing use of prasugrel or ticagrelor, 
diabetes, renal function, and history of peripheral vascular 
disease, and in an analysis stratiﬁ ed according to tertiles 
of the centres’ annual volume of percutaneous coronary 
intervention. Conversely, we found positive tests for trend 
across tertiles of the centres’ percentage of radial 
percutaneous coronary intervention for both coprimary 
outcomes and all-cause mortality (p≤0·0157), with a 
pronounced beneﬁ t of radial access in centres that did 
80% or more radial percutaneous coronary interventions 
(ﬁ gure 4, appendix). In a post-hoc analysis of the subgroup 
of 7213 patients who were randomly allocated to 
bivalirudin or unfractionated heparin, we found no 
evidence for an interaction between the eﬀ ect of radial 
versus femoral access and allocation to bivalirudin or 
unfractionated heparin for the two coprimary outcomes, 
all-cause mortality, or BARC 3 or 5 bleeding (p for 
interaction ≥0·64; data not shown).
Sensitivity analyses of the two coprimary outcomes, 
all-cause mortality, and BARC 3 or 5 bleeding were all 
compatible with the main analyses (appendix). Estimated 
numbers needed to treat were 71 for preventing one 
major adverse cardiovascular event, 56 for preventing one 
net adverse clinical event, 136 for preventing one BARC 
type 3 or 5 bleeding, and 169 for preventing one death, 
when using radial rather than femoral access (appendix).
In the nested case-control study of the 137 patients 
who died within 30 days from a cause other than 
bleeding and 1370 matched control patients, we found 
BARC 2 or 3 actionable bleeding associated with deaths 
from causes other than bleeding, with a crude OR of 
3·10 (95% CI 1·75–5·50; p<0·0001) and an adjusted OR 
of 2·35 (95% CI 1·18–4·67; p=0·015; appendix).
Discussion
Among patients with an acute coronary syndrome, with or 
without ST-segment elevation who underwent invasive 
management, the use of radial access for coronary 
angiography followed by percutaneous coronary inter-
vention, if indicated, signiﬁ cantly reduced the rate of net 
adverse clinical events, deﬁ ned as the composite of major 
adverse cardiovascular events or major bleeding, with a 
number needed to treat of 56. The 15% relative risk 
reduction for major adverse cardiovascular events did not 
meet the prespeciﬁ ed α level of 2·5% (p=0·031). 
Diﬀ erences between groups were driven by reductions in 
BARC major bleeding unrelated to coronary artery bypass 
graft surgery and all-cause mortality with radial access. No 
diﬀ erence was found with respect to rates of myocardial 
infarction or stroke, which appears reassuring in view of 
previous concerns that radial compared with femoral 
access might increase cerebrovascular embolisation.8,14 In 
a nested case-control study, we found BARC-actionable 
bleeding associated with deaths from causes other than 
bleeding, which suggests that a reduction in all-cause 
death with radial access could be mediated by a reduction 
of bleeding events, thus providing a mechanistic 
explanation for our ﬁ ndings.
In our meta-analysis of trials in patients with acute 
coronary syndromes (ﬁ gure 5, panel), updated with all 
trials that randomly assigned patients to radial or femoral 
access after the landmark RadIal Vs femorAL access 
for coronary intervention (RIVAL) study,8 we found a 
statistically robust and clinically relevant reduction in 
all-cause mortality by radial compared with femoral 
Figure 2: Coprimary composite outcomes at 30 days
(A) All-cause mortality, myocardial infarction, or stroke, and (B) all-cause mortality, myocardial infarction, stroke, 
or Bleeding Academic Research Consortium 3 or 5 bleeding.
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access, which could not be shown in a previous update 
done by the RIVAL investigators.8 Altogether, the results 
of our trial, in conjunction with the ﬁ ndings of the 
updated meta-analysis, suggest that radial access should 
become the default approach in patients with an acute 
coronary syndrome undergoing invasive management.
The clinical equipoise, or lack thereof, between radial 
and femoral access sites in patients undergoing coronary 
angiography or percutaneous coronary intervention, or 
both, has been debated extensively over recent years. Data 
from registries,7,16,17 small-to-medium-sized studies,18 and 
meta-analyses14,19 have suggested that radial access might 
be associated with improved outcomes when compared 
with femoral access. As a result, position papers, expert 
opinion papers, and guidelines from Europe2,20 or North 
America21–23 have endorsed the preferential use of radial 
over femoral access. However, the unexpected results of 
the large-scale RIVAL trial tempered enthusiasm towards 
use of radial access for coronary angiography and 
intervention, as neither the primary composite outcome 
of death, myocardial infarction, stroke, or major bleeding 
unrelated to coronary artery bypass graft surgery, nor the 
outcomes of major bleeding or all-cause death diﬀ ered 
signiﬁ cantly between the two access site groups.8 Widely 
overlapping 95% CIs for all outcomes suggest that results 
from RIVAL8 and our trial are mutually compatible and 
that diﬀ erences are mostly due to random variation. In 
view of a signiﬁ cant interaction for the primary outcome 
in the RIVAL trial, with a beneﬁ t for radial access in the 
highest-volume radial centres,8,15,24 some variation might 
also be explained by the levels of expertise with radial 
access. Additional explanations are the larger sample size 
of our study, combined with a higher rate of primary 
endpoint events, a higher proportion of patients in 
whom percutaneous coronary intervention was deemed 
indicated, and diﬀ erent bleeding deﬁ nitions.
In the RIVAL trial, operators were allowed to participate 
if they had done cumulatively 50 or more transradial 
catheterisations.25 In our trial, operators qualiﬁ ed on the 
basis of the number of transradial interventions done 
previously—not any catheterisation—with a cutoﬀ  of 
75 or more done in the year before study initiation at 
each site. This number is in keeping with the minimum 
annual number of percutaneous coronary intervention 
procedures recommended in the American College of 
Cardiology, American Heart Association, and Society of 
Cardiac Angiography and Intervention guidelines for an 
interventional cardiologist to enhance patient safety.26 
The proportion of percutaneous coronary interventions 
undertaken transradially emerged as a potential eﬀ ect 
modiﬁ er for both coprimary endpoints and overall 
mortality, but not for major bleeding. This ﬁ nding 
suggests that although the bleeding beneﬁ t accrues at an 
Figure 3: Components of coprimary composite at 30 days
(A) All-cause mortality, (B) myocardial infarction, (C) stroke, and (D) Bleeding 
Academic Research Consortium 3 or 5 bleeding.
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Figure 4: Stratiﬁ ed analysis of 
coprimary outcomes
(A) All-cause mortality, 
myocardial infarction, or 
stroke, and (B) all-cause 
mortality, myocardial 
infarction, or stroke, or 
Bleeding Academic Research 
Consortium 3 or 5 bleeding. 
PCI=percutaneous coronary 
intervention. ACS=acute 
coronary syndrome. 
STEMI=ST-segment elevation 
myocardial infarction. 
NSTE-ACS=non-ST-segment 
elevation acute coronary 
syndrome. *p values are for 
trend across ordered groups.
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earlier stage of the learning curve of transradial inter-
vention, superior eﬃ  cacy compared with femoral access 
needs substantial expertise that can be met only by 
high-volume radial operators, which is in keeping with 
recent observations from registry data.27
The Radial Versus Femoral Randomized Investigation 
in ST-Elevation Acute Coronary Syndrome (RIFLE-
STEACS) study,9 in which 1001 patients with ST-segment 
elevation myocardial infarction were randomly assigned 
to the radial or femoral approach, reported a decrease in 
the rate of major adverse cardiac events in the radial 
group, driven by reductions in mortality and bleeding. By 
contrast, the ST Elevation Myocardial Infarction treated 
by RADIAL or femoral approach (STEMI-RADIAL) trial28 
showed a signiﬁ cant reduction in bleeding and access site 
complications with radial access, but no mortality beneﬁ t 
was shown among 707 patients with ST-segment elevation 
myocardial infarction undergoing primary intervention 
within 12 h of symptom onset.
Anticoagulation strategies with low use of the direct 
thrombin inhibitor bivalirudin (<10%) and higher than 
contemporary use of glycoprotein IIb/IIIa inhibitors 
Figure 5: Forest plot of the updated meta-analyses of trials in patients with acute coronary syndromes
References for trial studies are listed in the appendix. CABG=coronary artery bypass graft. n/N=events/total number of patients. 
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Panel: Research in context
Systematic review
We searched PubMed and ISI Web of Science from Jan 1, 2001, to Feb 3, 2015 (see 
appendix for the search strategy) to update the meta-analyses previously done by the 
RIVAL trial,15 and used identical methods for data extraction and identical outcomes, 
except for restricting the analysis to trials in patients with acute coronary syndrome to 
ensure comparability with our trial and RIVAL,15 and omitting transfusion unrelated to 
coronary artery bypass graft surgery and major vascular access complication, since 
statistically robust reductions in these outcomes were previously shown.15 We used the 
Mantel-Haenszel method to pool risk ratios.
Interpretation
MATRIX Access is the largest randomised trial to compare radial and femoral access. The 
updated meta-analysis (ﬁ gure 5) shows that radial access reduces major bleeds, major 
adverse cardiovascular events, and all-cause mortality, but not myocardial infarction or 
stroke. The case-control study nested in MATRIX Access suggests that BARC 2 or 3 
actionable bleeding is strongly associated with mortality from causes other than 
bleeding. In conjunction, MATRIX Access and the updated meta-analysis suggest radial 
access should become the default access for patients with acute coronary syndrome 
undergoing invasive management. 
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(30–70%) might have favoured the radially treated 
patients when considering access site bleeding as an 
outcome, and might have contributed to the mortality 
diﬀ erence in the two groups in patients with ST-segment 
elevation myocardial infarction included in the RIVAL 
and RIFLE-STEACS studies.29 Bivalirudin was used 
during percutaneous coronary intervention in more than 
40% of patients in our trial; less than 14% received 
glycoprotein IIb/IIIa inhibitors at the time of inter-
vention, and more than 50% of the patients were treated 
with ticagrelor or prasugrel, more closely following 
contemporary clinical practice.
Before the MATRIX Access trial was done, the number 
of patients with non-ST-segment elevation acute 
coronary syndrome included in randomised trials of 
radial versus femoral access was restricted largely to 
those recruited in the RIVAL study, which showed 
similar rates of the primary outcome in the radial 
(3·8%) and femoral (3·5%) groups, and a trend towards 
higher mortality risk in those allocated to radial access 
(1·25% vs 1·66%; p=0·082).8 In multivariable analysis, 
the interaction between pre-randomisation acute 
coronary syndrome type and access site allocation on 
mortality remained highly signiﬁ cant, even after 
adjustment for operator radial experience and centre 
radial volume.15 The results of our trial do not lend 
support to the previous observation that the beneﬁ t of 
radial access, compared with femoral, in terms of 
combined outcomes or all-cause mortality might be 
variable across patients with acute coronary syndrome. 
All causes of death (ie, cardiac, vascular, and non-
cardiovascular) consistently contributed to the lower 
risk of all-cause mortality in the radial group. The 
magnitude of such beneﬁ t, in the range of six fewer 
fatal events for every 1000 treated patients, appeared 
less than previously reported in patients with 
ST-segment elevation myocardial infarction.9,15 However, 
in view of the millions of individuals with acute coronary 
syndrome undergoing invasive management, including 
the more than one million undergoing percutaneous 
coronary intervention annually worldwide, the mortality 
beneﬁ t reported with radial access site could have 
substantial consequences for public health. This beneﬁ t 
might be especially relevant for countries such as the 
USA where use of the radial approach is currently 
uncommon.30
Diﬀ erences did not reach statistical signiﬁ cance for 
major adverse cardiovascular events as one of the 
two coprimary outcomes, and one can argue that the 
results for secondary outcomes, including all-cause 
mortality, are not deﬁ nite since their α levels were not 
adjusted for multiple comparisons. However, our results 
need to be interpreted in the context of the updated 
meta-analysis (panel), which suggests highly signiﬁ cant 
beneﬁ ts of radial access in acute coronary syndrome 
patients for major adverse cardiovascular events 
(p=0·0051) and all-cause mortality (p=0·0011) with no 
evidence of statistical heterogeneity between trials. The 
higher than expected event rate in our study can be 
explained by the inclusion of a high-risk acute coronary 
syndrome population, including 10% of patients with 
Killip class greater than 1, 90% of patients with 
non-ST-segment elevation acute coronary syndrome 
with raised biomarker concentrations, and 2% with 
resuscitated cardiac arrest at presentation. It remains 
unclear how the risk proﬁ le of the included patients 
compares with an all-comer acute coronary syndrome 
population given the absence of a screening log at 
recruiting sites in our trial.
In conclusion, our results show that in patients with 
acute coronary syndrome, with or without ST-segment 
elevation, undergoing invasive management, the use of 
radial access compared with femoral access decreases net 
adverse clinical events.
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